{"canonical":"https://abierto.us/vendors/spero-therapeutics-inc-nx34pl7nzw24","key":"NX34PL7NZW24","name":"SPERO THERAPEUTICS, INC.","uei":"NX34PL7NZW24","city":"CAMBRIDGE","state":"MA","awards":2,"obligated":"20944971.50","notices_won":0,"top_agency_name":"Office of Assistant Secretary for Preparedness and Response","top_naics":"541714","cage":"7SK81","parent_name":"SPERO THERAPEUTICS, INC.","also_known_as":[],"country":"USA","actions":13,"first_action":"2024-07-03","last_action":"2026-07-20","breakdowns":{"naics":[{"key":"541714","name":null,"awards":1,"obligated":"17520434.50"},{"key":"541715","name":null,"awards":1,"obligated":"3424537.00"}],"places":[{"key":"MA","name":null,"awards":2,"obligated":"20944971.50"}],"agencies":[{"key":"7505","name":"Office of Assistant Secretary for Preparedness and Response","awards":1,"obligated":"17520434.50"},{"key":"7529","name":"National Institutes of Health","awards":1,"obligated":"3424537.00"}],"award_types":[{"key":"DEFINITIVE CONTRACT","name":null,"awards":2,"obligated":"20944971.50"}],"competition":[{"key":"FULL AND OPEN COMPETITION","name":null,"awards":2,"obligated":"20944971.50"}],"product_service_codes":[{"key":"AN13","name":null,"awards":1,"obligated":"17520434.50"},{"key":"AN11","name":null,"awards":1,"obligated":"3424537.00"}]},"awards_list":[{"award_key":"CONT_AWD_75A50118C00015_7505_-NONE-_-NONE-","permalink":"https://www.usaspending.gov/award/CONT_AWD_75A50118C00015_7505_-NONE-_-NONE-/","piid":"75A50118C00015","parent_piid":null,"award_type":"DEFINITIVE CONTRACT","vendor_key":"NX34PL7NZW24","recipient_name":"SPERO THERAPEUTICS, INC.","recipient_uei":"NX34PL7NZW24","recipient_cage":"7SK81","recipient_city":"CAMBRIDGE","recipient_state":"MA","sub_name":"Office of Assistant Secretary for Preparedness and Response","office_name":"BARDA - ASPR / DAAPPO / BARDA DCMA","office_key":"o-75A501","first_action_date":"2024-07-03","last_action_date":"2026-07-06","actions":8,"obligated":"17520434.50","current_total_value":"49196133.50","potential_total_value":"49196133.50","naics":"541714","psc":"AN13","extent_competed":"FULL AND OPEN COMPETITION","set_aside":"NO SET ASIDE USED.","offers_received":1,"description":"MODIFICATION P00015 THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO: A) INCREASE THE US GOVERNMENT FUNDING FOR CLIN 0005 OPTION 4 FROM $12,498,467 BY $11,697,110 TO $24,195,577 AND THE SPERO COST SHARE FROM $63,204,595 BY $14,683,133 TO $77,887,","method":null,"confidence":null,"evidence":null,"opportunity_key":null,"opportunity_title":null},{"award_key":"CONT_AWD_75N93021C00022_7529_-NONE-_-NONE-","permalink":"https://www.usaspending.gov/award/CONT_AWD_75N93021C00022_7529_-NONE-_-NONE-/","piid":"75N93021C00022","parent_piid":null,"award_type":"DEFINITIVE CONTRACT","vendor_key":"NX34PL7NZW24","recipient_name":"SPERO THERAPEUTICS, INC.","recipient_uei":"NX34PL7NZW24","recipient_cage":"7SK81","recipient_city":"CAMBRIDGE","recipient_state":"MA","sub_name":"National Institutes of Health","office_name":"NATIONAL INSTITUTES OF HEALTH NIAID","office_key":"o-75N930","first_action_date":"2024-07-11","last_action_date":"2026-07-20","actions":5,"obligated":"3424537.00","current_total_value":"10501521.27","potential_total_value":"27032719.27","naics":"541715","psc":"AN11","extent_competed":"FULL AND OPEN COMPETITION","set_aside":"NO SET ASIDE USED.","offers_received":23,"description":"TO ADVANCE CLINICAL AND NON-CLINICAL DEVELOPMENT OF AN ANTIBIOTIC CANDIDATE.","method":null,"confidence":null,"evidence":null,"opportunity_key":null,"opportunity_title":null}],"awards_total":2,"awards_page":1,"won":[],"won_total":0,"solicitations_won":[]}